Who is sponsoring NCT04476082?

NCT04476082 is sponsored by University Medicine Greifswald.

What drugs are being tested in NCT04476082?

Interventions in NCT04476082: No intervention - observational study only.

What condition does NCT04476082 study?

NCT04476082 studies Pancreatic Cancer, Oesophageal Cancer, Colon Cancer, Liver Cancer, Rectal Cancer, Bile Duct Cancer, GIST, Malignant, Neuroendocrine Tumors, Small Intestine Cancer, Gastric Cancer.

Is NCT04476082 still recruiting?

NCT04476082 is currently completed. Last updated 25 January 2023.

Last reviewed 2023-01-25 · How we verify

NCT04476082: NutriGIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nutrition in Gastrointestinal Tumors

Completed Last updated 25 January 2023

What this trial tests

trial testing No intervention - observational study only in Pancreatic Cancer in 66 participants. Completed in 6 December 2022.

Timeline

25 June 2020

Primary endpoint
6 December 2022

6 December 2022

Quick facts

Lead sponsor	University Medicine Greifswald
Status	Completed
Study type	OBSERVATIONAL
Enrollment	66
Start date	25 June 2020
Primary completion	6 December 2022
Estimated completion	6 December 2022
Sites	1 location across Germany

Drugs / interventions tested

No intervention - observational study only

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Oesophageal Cancer — all drugs for Oesophageal Cancer →
Colon Cancer — all drugs for Colon Cancer →
Liver Cancer — all drugs for Liver Cancer →

Sponsor

University Medicine Greifswald

Who can join

18 and older, any sex, with Pancreatic Cancer or Oesophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Malnutrition and loss of muscle mass frequently occur in patients undergoing chemotherapy and can negatively effect therapy outcome. Especially patients with cancer of the gastrointestinal tract are often affected by malnutrition. Therefore, this study aims to examine changes in nutritional status of patients with cancer of the gastrointestinal tract during chemotherapy. Findings of this study will help to improve nutritional treatment of patients undergoing chemotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Pancreatic Cancer and Gut Microbiome-Related Aspects: A Comprehensive Review and Dietary Recommendations.
Sobocki BK, Kaźmierczak-Siedlecka K, Folwarski M, Hawryłkowicz V, et al · · 2021 · cited 30× · PMID 34959977 · DOI 10.3390/nu13124425
Gastrectomy impact on the gut microbiome in patients with gastric cancer: A comprehensive review.
Maksimaityte V, Bausys A, Kryzauskas M, Luksta M, et al · · 2021 · cited 26× · PMID 34354801 · DOI 10.4240/wjgs.v13.i7.678
Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications.
Amara S, Yang LV, Tiriveedhi V, Muzaffar M. · · 2022 · cited 8× · PMID 35741028 · DOI 10.3390/cells11121900
Malnutrition in gastrointestinal cancer manifests before systemic therapy and is associated with fatigue and reduced physical quality of life.
Wiese ML, Schwarz L, von Rheinbaben S, Schmidt S, et al · · 2026 · PMID 41630516 · DOI 10.1093/oncolo/oyag028

Verify or expand the search:

Other trials of No intervention - observational study only

Trials testing the same drug.

NCT05613673 — Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis · active not recruiting
NCT05501379 — Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker · recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other University Medicine Greifswald trials

Trials by the same sponsor.

NCT06796374 — A Comparison of Fisetin Kinetics in Young and Old Adults · NA · recruiting
NCT06970171 — Acceptance of Mandibular Advancement Devices · NA · not yet recruiting
NCT06939608 — Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions · NA · completed
NCT06273241 — Impact of Food Intake on Berberine Kinetics · NA · completed
NCT06249451 — Staphylococcus Aureus Bacteraemia (SAB)-Support-Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04476082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medicine Greifswald
Last refreshed: 25 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04476082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing